Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888826 | 1.00 | PDE4D (0.45) | PDE4DPDE4BPDE4APDE4CADRB2 | |
| SCHEMBL2888825 | 1.00 | PDE4D (0.45) | PDE4DPDE4BPDE4APDE4CADRB2 | |
| SCHEMBL2881520 | 0.93 | PDE4D (0.51) | PDE4DPDE4BPDE4APDE4CADRB2 | |
| SCHEMBL2881526 | 0.93 | PDE4D (0.51) | PDE4DPDE4BPDE4APDE4CADRB2 | |
| SCHEMBL2881522 | 0.93 | PDE4D (0.51) | PDE4DPDE4BPDE4APDE4CADRB2 | |
| SCHEMBL2888763 | 0.82 | PDE4D (0.38) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2888767 | 0.82 | PDE4D (0.38) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2888766 | 0.82 | PDE4D (0.38) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5036837 | 0.82 | PDE4D (0.53) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5036841 | 0.82 | PDE4D (0.53) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | ALTANA PHARMA AG (DE) | 2006-12-14 | — | — | US | disclosed |
| EP-1650193-A2 | 6-Phenylphenanthridines with PDE-IV inhibiting activity | ALTANA Pharma AG (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1147089-B1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-6476025-B1 | Phenylphennanthridines with PDE-IV inhibiting activity | ALTANA PHARMA AG (DE) | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | PDE4A, PDE4B, PDE12 | PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.